Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) Operating Expenses (2023 - 2025)

Metagenomi (MGX) has disclosed Operating Expenses for 3 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 6.48% to $28.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $121.2 million, a 14.15% decrease, with the full-year FY2025 number at $121.2 million, down 14.15% from a year prior.
  • Operating Expenses was $28.3 million for Q4 2025 at Metagenomi, down from $31.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $40.2 million in Q1 2024 to a low of $26.6 million in Q1 2023.
  • A 3-year average of $32.1 million and a median of $31.7 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 51.12% in 2024, then decreased 20.51% in 2025.
  • Metagenomi's Operating Expenses stood at $32.6 million in 2023, then dropped by 7.23% to $30.2 million in 2024, then fell by 6.48% to $28.3 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Operating Expenses are $28.3 million (Q4 2025), $31.5 million (Q3 2025), and $29.5 million (Q2 2025).